Pages that link to "Q33557369"
Jump to navigation
Jump to search
The following pages link to The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer (Q33557369):
Displaying 11 items.
- YY1-binding sites provide central switch functions in the PARP-1 gene expression network (Q21134068) (← links)
- Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. (Q33944203) (← links)
- Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009 (Q34390396) (← links)
- Personalized therapy in endometrial cancer: Challenges and opportunities (Q35911350) (← links)
- Combination Drug Delivery Approaches in Metastatic Breast Cancer (Q35955198) (← links)
- Harnessing synthetic lethal interactions in anticancer drug discovery (Q36839571) (← links)
- Expression of Poly (Adenosine Diphosphate-Ribose) Polymerase and p53 in Epithelial Ovarian Cancer and Their Role in Prognosis and Disease Outcome (Q37308690) (← links)
- PARP and PARG inhibitors--new therapeutic targets in cancer treatment (Q37728981) (← links)
- Management of genetic syndromes predisposing to gynecologic cancers (Q38073703) (← links)
- Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. (Q55377222) (← links)
- The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer (Q89004561) (← links)